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Summary
Moderate alcohol consumption is associated with lower levels
of several coagulation factors. It is an established protective fac-
tor for cardiovascular disease; however, the effect on venous
thrombosis is unknown. In a large population-based case-con-
trol study, we evaluated the association between alcohol con-
sumption and the risk of venous thrombosis.The MEGA study
included consecutive patients with a first venous thrombosis be-
tween March 1999 and September 2004 from six anticoagu-
lation clinics in the Netherlands.Partners of patients were asked
to participate, and additional controls were recruited using a
random digit dialling method.All participants completed a stan-
dardized questionnaire, and blood samples were collected. A
total of 4,423 patients and 5,235 controls were included in the
analyses. Alcohol consumption was associated with a reduced
risk of venous thrombosis, with 2–4 glasses per day resulting in
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the largest beneficial effect (odds ratio [OR] 0.67, 95% con-
fidence interval [CI95] 0.58–0.77) compared to abstainers.The
effect was more pronounced in women (OR 0.66, CI95
0.53–0.84) than men (OR 0.82, CI95 0.63–1.07) and also more
striking for pulmonary embolism (OR 0.56, CI95 0.46–0.70)
than for deep venous thrombosis of the leg (OR 0.74, CI95
0.63–0.88). Compared to abstainers, fibrinogen levels were de-
creased in individuals who consumed alcohol (maximum de-
crease:0.30 g/l).FactorVII and vonWillebrand levels were mildly
decreased in these individuals but not consistently over the cat-
egories of alcohol consumption. In conclusion, alcohol con-
sumption is associated with a reduced risk of venous thrombo-
sis, which may be in part mediated by decreased fibrinogen lev-
els.
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Introduction
The protective effect of moderate and the harmful effect of heavy
alcohol consumption on the risk of arterial disease has been
shown in many epidemiological studies (1). Similar effects of al-
cohol consumption on the risk of venous thrombosis are also not
unlikely considering the effect of alcohol consumption on co-
agulation factors. A systematic review reported an association
between moderate alcohol intake and reduced levels of fibri-
nogen, factor VII and von Willebrand factor, whereas heavy and
binge alcohol drinking was associated with increased levels of
fibrinogen and factor VII (2).
Few studies have reported on the relationship between alco-
hol consumption and venous thrombosis. In an Italian cohort
study of elderly individuals, low to moderate alcohol consump-
tion appeared beneficial with relative risks of 0.7 for less than
one drink a month, 0.6 for less than one ounce per day and 0.5 for
one or more than one ounce per day (3). In contrast, two US co-
hort studies found no effect of alcohol consumption on the risk of
venous thrombosis (4, 5). In these cohort studies alcohol intake
was only assessed at baseline and variations of alcohol intake
during follow-up may have resulted in misclassification of alco-
hol levels and spurious estimates. In a French case-control study
no effect of alcohol consumption was found (6). In this study, the
control group consisted of patients with influenzal or rhino-
pharyngeal symptoms in whom alcohol consumption may differ
from the base population of cases. Alcohol is consumed regu-
larly by two billion people worldwide (7), which makes it impor-
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tant to elucidate the relationship between alcohol consumption
and the risk of venous thrombosis. In the Multiple Environment-
al and Genetic Assessment of risk factors for venous thrombosis
(MEGA study), a large population-based case-control study, we
investigated alcohol use as a risk factor for venous thrombosis. In
addition we analyzed the association of alcohol consumption
with fibrinogen, factor VII and von Willebrand factor levels to
verify if a protective effect could be explained by changes in
these coagulation parameters.
Methods
Study design
Details of the MEGA study have been published (8). Between
March 1999 and September 2004, consecutive patients with a
first deep venous thrombosis (DVT) of the leg or a pulmonary
embolism (PE) were included from six anticoagulation clinics.
All patients were between the age of 18 and 70. Patients with se-
vere psychiatric problems or those unable to speak Dutch were
considered as ineligible. Partners of patients were asked to par-
ticipate as control subjects. From January 2002 until September
2004, an additional control group was recruited using a random
digit dialling method. Phone numbers were dialed at random
within the geographical inclusion area of the patients. During the
phone call a specific person within a household (e.g. youngest
woman between 20 and 50) was asked to participate.The random
control subjects were frequency matched to the patients with re-
spect to age and sex. Only control subjects with no recent history
of venous thrombosis were included and the same exclusion
criteria applied as for the patients.
Among the 6,055 eligible patients 5,051 participated (83%).
Of the 5,051 participating patients, 3,656 had an eligible partner
of whom 2,982 participated (82%). Of the 4,346 eligible random
control subjects 3,000 participated (69%).
All participants gave written informed consent and the study
was approved by the Medical Ethics Committee of the Leiden
University Medical Center, Leiden, The Netherlands.
Data collection
Within a few weeks after diagnosis and registration at the antico-
agulation clinics patients received a letter with information
about the study and were subsequently contacted by phone. If the
patient was willing to participate, a questionnaire was sent. The
control subjects received the questionnaires immediately after
inclusion by phone. The questionnaire was returned by 4,637 pa-
tients (77%), 2,821 partners (77%) and 2,789 random control
subjects (64%). The participants who did not return a question-
naire were asked questions by phone. This short interview did
not include questions regarding alcohol consumption.
The question referring to alcohol consumption included ten
categories of alcohol consumption: none, one glass or less per
week, 2–6 glasses per week, one glass per day, 2–4 glasses per
day, 5–9 glasses per day, 10–19 glasses per day, 20–29 glasses
per day, 30–39 glasses per day and 40 or more glasses per day.
Because only 85 individuals filled in an amount in the highest
four categories of alcohol consumption these categories were
taken together in the analysis. The questionnaire did not ask
about kind of alcohol used. Participants who returned the ques-
tionnaire with missing data on alcohol consumption, body
weight or height, smoking or pregnancy were excluded from all
analyses. The total excluded proportion was the same in patients
(4.6%) and control subjects (4.7%). In the analyses only partner
controls with a participating patient were included leading to a
total of 4,423 patients, 2,576 partner and 2,659 random control
subjects for the present analyses.
Blood collection
At least three months after withdrawal of anticoagulation the pa-
tients and their partners were asked to visit the anticoagulation
clinic after an overnight fast where a blood sample was drawn.
Only in case of continuous use for more than one year a blood
sample was taken during anticoagulation therapy. From De-
cember 1999 onwards, we obtained self-administered buccal
swabs by mail when participants were unable or unwilling to
come for a blood draw. From June 2002 onwards, blood draws
were no longer performed in patients and their partners, and the
study was restricted to DNA collection by buccal swabs sent by
mail. The random controls were invited for a blood draw within
a few weeks after the questionnaire was sent. Within this group
buccal swabs were sent when someone refused the blood draw.
In the control subjects 2,614 blood samples were obtained
(50%). Fibrinogen, von Willebrand factor and factor VII were
successfully determined in 2,612 samples. Fibrinogen activity
was measured on the STA-R analyzer according to methods of
Clauss (9). The intra-assay coefficient of variation (CV) was 1.8,
the inter-assay CV was 3.8. Factor VII activity (FVII) was
measured with a mechanical clot detection method on the STA-R
analyzer following the instructions of the manufacturer (Diag-
nostica Stago,Asnieres, France).The intra-assay CV was 3.4, the
inter-assay CV was 4.0. Von Willebrand factor antigen (vWF)
was measured with the immuno-turbidimetric method, using the
STA liatest kit (rabbit anti-human vWF antibodies), following
the instructions of the manufacturer. For vWF the intra- and
inter-assay CV were 3.6 and 2.6.
Statistical analysis
Odds ratios (OR) were calculated as estimates of the relative risk
with 95% confidence intervals (CI95) according to the method of
Woolf. Using a multiple logistic regression model ORs were ad-
justed for age (continuous), sex (categorical), body mass index
(BMI=kg/m
2
) (continuous), pregnancy (categorical) and smok-
ing (categorical). Adjustment for age (10 categories) and body
mass index (8 categories) as categorical variables resulted in ap-
proximately the same risk estimates. Additional adjustment for
disease history, including malignancies, did not change the risk
estimates. In the analyses with the random control subjects an un-
matched analysis including 4,423 patients and 2,659 random con-
trol subjects was performed. In the analyses with partners as the
control group (2,576 pairs), we performed a matched analysis
which adjusts for similar life-style factors between patients and
their partners (10). Because the results of the matched and the un-
matched analyses showed consistently protective relative risks in
all analyses, we calculated pooled risk estimates with a method
that combines the matched and unmatched analyses (11). When
analyzing the risk in men and women separately it was not possi-
ble to perform a matched analysis with the partner controls, there-
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fore risk estimates were calculated with an unmatched analysis
with all patients and the random control subjects.
A Chi
2
-test was used to compare alcohol consumption be-
tween patients with DVT of the leg with those in patients with
PE.
SAS 9.1 (SAS institute Inc, Cary, NC, USA) was used for all
statistical analyses.
Results
In the current analysis 4,423 patients with a first venous throm-
bosis and 5,235 control subjects were included. Mean age of the
patients was 48.5 years (5
th
-95
th
percentiles, 25.8–67.7) and the
control subjects were on average 46.8 years (5
th
-95
th
percentiles,
25.4–66.4). In the patient and in the control group 54% were
women (n
patient
=2400, n
control
=2816). In the patient group 57%
(n=2528) was diagnosed with DVT of the leg, nearly a third
(n=1340) with PE and 13% (n=555) with the combined diag-
nosis of DVT and PE.
Figure 1 shows the relationship between alcohol consump-
tion and the risk of venous thrombosis. Moderate alcohol con-
sumption was associated with a decreased risk of venous throm-
bosis, with two to four glasses per day resulting in the strongest
effect on the risk of venous thrombosis (OR
2–4/day
0.67, CI95
0.58–0.77) compared to abstainers. Even drinking more than
four glasses per day appeared to be still somewhat protective
(OR
5–9/day
0.82, CI95 0.65–1.04, OR
≥10/day
0.71, CI95 0.45–1.12).
Moderate alcohol consumption was associated with a somewhat
more decreased risk for women (OR
2–4/day
0.66, CI95 0.53–0.84)
than men (OR
2–4/day
0.82, CI95 0.63–1.07).
The associations of alcohol consumption with the risk of
DVT and PE separately are presented in Figure 2. The protective
effect of alcohol consumption appeared to be more pronounced
for the diagnosis of PE (OR
2–4/day
0.56, CI95 0.46–0.70) than for
DVT (OR
2–4/day
0.74, CI95 0.63–0.88). Drinking two glasses per
week or more clearly protected more against PE than against
DVT (p=0.02).
In Figure 3 mean fibrinogen, factor VII and von Willebrand
factor levels are presented for different categories of alcohol
consumption in control subjects. Alcohol consumption cat-
egories which were associated with the most pronounced reduc-
tion in venous thrombotic risk were also associated with reduced
levels of fibrinogen. Factor VII levels and von Willebrand factor
levels were also lower in drinkers than non-drinkers, but there
were no consistent patterns over the categories of alcohol con-
sumption.
Discussion
In this large case-control study moderate alcohol consumption
was associated with a decreased risk of venous thrombosis. This
potential beneficial effect of moderate alcohol consumption ap-
peared to be more pronounced in women than men and for PE
than for DVT of the leg.
Very little is known about the mechanisms by which alcohol
may exert antithrombotic effects. Some studies have shown that
moderate alcohol consumption is associated with a more favor-
able coagulation profile, indicated by lower levels of fibrinogen,
factorVII and von Willebrand factor (12, 13). In accordance with
these studies we found reduced levels of fibrinogen, factor VII
and von Willebrand factor in moderate alcohol drinkers. Re-
duced levels were most striking for fibrinogen, where levels were
even decreased up to high levels of alcohol consumption (5–9
glasses per day).
The difference between men and women in the alcohol-re-
lated risk of venous thrombosis may be explained by the differ-
ential effects of wine and beer (14), the latter of which is con-
sumed more by men than women. Unfortunately, in our study we
had no information about the kind of alcoholic drinks the partici-
Figure 1: Relative risk of venous thrombosis by level of alcohol
consumption. *adjusted for age, sex, body mass index, smoking and
pregnancy; I, CI95; n
p
, number of patients; n
c
, number of control sub-
jects; ref., reference category.
Figure 2: Relative risk of deep venous thrombosis (DVT) and
pulmonary embolism (PE) by level of alcohol consumption. *ad-
justed for age, sex, body mass index, smoking and pregnancy; I, CI95;
ref., reference category.
pants consumed. A question about type of alcoholic drinks could
have provided important additional information. A recent study
however, showed that wine, beer and spirits were to the same ex-
tent protective for myocardial infarction, suggesting that type of
alcohol drink did not influence the effect (15).
It was striking that the protective effect of drinking two or
more glasses of alcohol per week was higher for PE than for DVT
of the leg. We do not have an explanation for these findings.
A limitation of our study is that alcohol consumption was
self-reported. Although it is possible that individuals under-
report alcohol consumption, this is mainly a problem when there
is a difference between patients and control subjects in reporting
behavior. If patients and controls both had underreported, the
protective effect we observed was underestimated. If patients
underreported more than controls, the true effect would have
been less pronounced. The proportion of individuals who failed
to report their alcohol consumption was the same in patients
(0.71%) and controls (0.66%), which suggests that the two
groups behaved similarly in answering this question.
In conclusion, in this large population-based case-control
study alcohol consumption is associated with a decreased risk of
venous thrombosis, with two to four glasses per day resulting in
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the largest effect. This effect may be mediated by a decrease in
coagulation factors, especially fibrinogen.
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Figure 3: Mean levels of haemostatic variables according to
alcohol consumption in control subjects. I, standard error of the
mean. N=2612.
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